Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...

Jefferies London Healthcare Conference 2025 November 19, 2025 4:30 AM ESTCompany ParticipantsTony Wood - Chief Scientific Officer and Head ...

SAS Viya Essentials rapidly deploys select SAS Viya products using SAS Managed Cloud Services Thursday, 20 November 2025 - SAS, a global ...

In this article, ReiThera's scientific and operational leaders discuss ReiThera’s proprietary platforms, process development ...

This collaboration supports the advancement of the EpiCapture test, which is currently in late-stage development, to regulatory approval and commercialization. This initiative is part of Trinity ...

Data from a new surveillance report show rising resistance to ceftriaxone and cefixime, the two antibiotics currently ...

For gangs, the Misuse of Drugs Act (1975) has been one of the best recruiting tools they’ve ever had. Criminalisation of a raft of illicit drugs not only provide s them with a wildly lucrative black ...

At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...

Every year, during International Burns Awareness Week, which is from November 3 to 9, we are reminded of the need for safety ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.